Rapid influenza diagnostic tests (RIDTs) had low test sensitivity for detecting 2009 pandemic influenza A (H1N1pdm09) infection, causing public health authorities to recommend that treatment decisions be based primarily upon risk for influenza complications . We used multivariate Poisson regression analysis to estimate the contribution of RIDT results and risk for H1N1pdm09 complications to receipt of early antiviral (AV) treatment among 290 people with influenza-like illness (ILI) who received an RIDT #48 hours after symptom onset from May to December 2009 at four southwestern U.S. facilities. RIDT results had a stronger association with receipt of early AVs (rate ratio [RR] 5 3.3, 95% confidence interval [CI] 2.4, 4.6) than did the presence of risk factors for H1N1pdm09 complications (age ,5 years or high-risk medical conditions) (RR51 .9, 95% CI 1 .3, 2 .7) . Few at-risk people (28/126, 22%) who had a negative RIDT received early AVs, suggesting the need for sustained efforts by public health to influence clinician practices .
Widespread reliance on rapid influenza diagnostic tests (RIDTs) complicated outbreak control and medical management during 2009 pandemic influenza A (H1N1pdm09). 1 On April 29, 2009, the Centers for Disease Control and Prevention (CDC) advised clinicians to consider RIDT screening of patients with signs and symptoms compatible with influenza, but warned to interpret results with caution given limited test accuracy. 2 CDC recommended antiviral (AV) treatment for children aged ,5 years and people with certain medical conditions, two groups at higher risk for adverse influenza-related outcomes. 3 In May 2009, CDC confirmed low sensitivity (40%-69%) in three different RIDTs for detecting H1N1pdm09, with sensitivities subsequently reported at 11%-88%. [4] [5] [6] [7] The Indian Health Service (IHS) is responsible for providing health care to eligible American Indian/ Alaska Native (AI/AN) people through IHS, Tribal, and Urban Indian health facilities (collectively referred to as IHS). These facilities cared for approximately 60% of the U.S. AI/AN population, or 1.5 million beneficiaries, in 2009. 8 On average, AI/ANs have lower income levels, education, and employment than the general U.S. population 9 and are recognized to be at elevated risk of influenza complications and death. 10 In June 2009, after multiple RIDT-negative cases of severe, probable H1N1pdm09 respiratory illness were reported, IHS issued clinical guidance recommending that patients with influenza-like illness (ILI) be tested for H1N1pdm09 virus and presumptively treated with AVs if they met CDC treatment criteria. To estimate the contribution of RIDT results to AV treatment decisions, IHS retrospectively analyzed ILI case data from four southwestern IHS facilities to measure the association among an RIDT result, presence of risk factors, and receipt of early AV therapy. Of 290 people with ILI with an RIDT #48 hours after symptom onset (but not before symptom onset), 84 (29%) were RIDT positive and 206 (71%) were RIDT negative. Early AVs were received by 48/84 (57%) people with a positive RIDT and by 37/206 (18%) people with a negative RIDT (Figure) . During the spring wave, early AVs were received by 13/35 (37%) people with a positive RIDT and by 5/96 (5%) people with a negative RIDT ( Table 2) . During the fall wave, early AVs were received by 35/49 (71%) people with a positive RIDT and by 32/110 (29%) people with a negative RIDT. During the entire period, after adjusting for conditions conferring elevated risk for adverse outcomes (aged ,5 years or with medical risk factors), an RIDT result had a stronger association with receipt of early AVs (rate ratio [RR] 5 3.3, 95% confidence interval [CI] 2.4, 4.6) than did the presence of these risk factors (RR51.9, 95% CI 1.3, 2.7). These differences were more striking in the spring wave (RR57.4, 95% CI 2.9, 18.9 vs. RR52.5, 95% CI 0.9, 6.7) than in the fall wave (RR52.5, 95% CI 1.8, 3.5 vs. RR51.8, 95% CI 1.2, 2.5) ( Table 2 ). Overall, 33 of 46 people (72%) at risk for adverse outcomes with a positive RIDT received early AVs, whereas 28 of 126 people (22%) at risk for adverse outcomes with a negative RIDT received early AVs (Table 3 ).
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We found that an RIDT result had a stronger association with receipt of early AV treatment than did the presence of risk factors for H1N1pdm09 complications, particularly during the spring wave. The low sensitivity (11%-88%) of conventional RIDTs in detecting H1N1pdm09 is now well documented. [4] [5] [6] [7] Our data indicate that people with a negative RIDT were frequently left untreated, despite having indications for AV treatment and having presented within 48 hours of illness onset. This undertreatment of people with a negative RIDT occurred despite public health guidance that clinicians rely on the risk status of people with ILI rather than on an RIDT result when making treatment decisions. 2 These findings are especially important when considering that AI/ANs are a recognized influenza complication risk group. 10 The low rate of AV treatment among RIDT-negative people with ILI may represent missed treatment opportunities. Compared with AV treatment decisions made during the spring wave, decisions made during the fall wave were less reliant on RIDT results, likely due to the effect of public health messaging discouraging their use in making treatment decisions. A retrospective cohort study in Los Angeles, California, described AV treatment practices at variance with CDC guidance for treatment of high-risk groups, but treatment among high-risk patients (94% of inpatients and 54% of outpatients) was more common than we observed. 14 The role of RIDTs in clinical decision-making during the pandemic was not explored in their analysis and has been seldom studied (for any epidemic).
Our findings also suggest missed treatment opportunities, even with positive RIDT results, as 28% of at-risk people with a positive RIDT still did not receive early AV treatment. We speculate that IHS providers might have restricted AV treatment based on current or anticipated shortages, particularly early in the pandemic. Understanding the relative contributions of RIDTs and risk factors in providers' treatment decisions can help inform future influenza treatment recommendations.
Weak rapid diagnostic tests (RDTs) are not unique to influenza and demonstrate the conflict between maximizing rapid, accurate diagnosis and minimizing missed or false diagnoses. For example, Dinnes et al. identified limitations to the performance of various RDTs in tuberculosis conditions. 15 The performance of any RDT is dependent on a variety of community, host, 
Limitations
This study was subject to several limitations. One limitation was that reliance on retrospective chart review limited analyses to data recorded in clinical charts. Another limitation was that the cohort size precluded accurate assessment of some clinical endpoints (e.g., hospitalization, intensive care unit hospitalization, or death). A third limitation was that we focused on the experience of four facilities serving an AI/AN population; as such, this study might not be generalizable to all AI/ANs in the U.S. Lastly, our study population contained a larger proportion of younger people than among overall U.S. H1N1pdm09 cases, 16 which is reflective of our service population, but which may impact the generalizability of these findings to the general U.S. population.
concluSionS
Studies in the United States, China, and Mexico indicate that during H1N1pdm09, early AV treatment was associated with a reduction in severe influenza complications, especially intensive care unit admission and death. [16] [17] [18] While early AV treatment is most effective, treatment can still be beneficial up to ,5 days after symptom onset. 17 In 2011, the Advisory Committee on Immunization Practices updated its recommendations for prescribing AVs in the case of clinically suspected or confirmed influenza to include all people who are hospitalized; have severe, complicated, or progressive disease; or are at higher risk for influenza complications. 10 High-risk groups now include AI/ANs. Our findings highlight the challenges involved in making clinical decisions during a rapidly evolving public health emergency. In the case of influenza pandemics and other major public health events, public health authorities are a crucial source of guidance for clinical providers who are trying to keep up with increased patient load while simultaneously trying to follow rapidly changing recommendations. These results emphasize the importance of sustained efforts by public health authorities to educate clinical providers to consider not just the results of rapid testing, but a patient's entire risk profile as well.
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